You are here: Home » Companies » News
Business Standard

Glenmark Pharma gets USFDA nod for generic antibiotic cream

Glenmark Pharma said it has received approval from the US health regulator to market Clindamycin Phosphate Foam, an antibiotic used for treating bacterial infections, in the American market

Topics
Glenmark Pharmaceuticals | USFDA

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals

on Tuesday said it has received approval from the US health regulator to market Clindamycin Phosphate Foam, an antibiotic used for treating bacterial infections, in the American market.

The Mumbai-based firm has received final approval from the US Food and Drug Administration (USFDA) to market Clindamycin Phosphate Foam (1 per cent) which is a generic version of Mylan Pharmaceuticals Inc's Evoclin Foam.

According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, (1 per cent) had achieved annual sales of around USD 12 million.

Glenmark's current portfolio consists of 173 products authorised for distribution in the US market place and 47 abbreviated new drug applications (ANDAs) are pending for approval with the

In addition to these internal filings, the drug maker continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it stated.

Shares of the company were trading 1.03 per cent up at Rs 500.05 apiece on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 21 2021. 13:08 IST
RECOMMENDED FOR YOU
.